Dosing of Zinc Acetate and Penicillamine in Wilson's Disease
For penicillamine, start with 250-500 mg/day and titrate up by 250 mg increments every 4-7 days to a maximum of 1000-1500 mg/day in 2-4 divided doses, with maintenance typically at 750-1000 mg/day; for zinc acetate, use 150 mg elemental zinc daily in three divided doses for adults and children >50 kg, or 75 mg/day in three divided doses for children <50 kg, taken 30 minutes before meals. 1, 2
Penicillamine Dosing
Initial Dosing Strategy
- Begin with incremental dosing of 125-250 mg/day (or 250-500 mg/day), increased by 250 mg increments every 4-7 days to minimize early sensitivity reactions 1
- Target dose: 1000-1500 mg/day divided into 2-4 doses 1
- Never exceed 1500 mg/day at once, as this can lead to rapid and often irreversible neurological deterioration 1
Maintenance Dosing
- Adults: 750-1000 mg/day in 2 divided doses 1
- Children: 20 mg/kg/day rounded to nearest 250 mg, given in 2-3 divided doses 1
Administration Timing
- Take 1 hour before or 2 hours after meals to maximize absorption, as food reduces absorption by approximately 50% 1
- Closer proximity to meals is acceptable if it ensures compliance 1
- Require pyridoxine supplementation at 25-50 mg daily 1
Critical Warnings
- 20-30% of patients develop severe side effects requiring discontinuation 1
- Neurological worsening occurs in 10-50% of patients during initial treatment, with one recent series showing 13.8% adversely affected 1
- Immediate discontinuation required for: early sensitivity reactions (fever, rash, lymphadenopathy, neutropenia, thrombocytopenia, proteinuria within 1-3 weeks), nephrotoxicity, severe bone marrow toxicity 1
Zinc Acetate Dosing
Standard Dosing
- Adults and children >50 kg: 150 mg elemental zinc daily in three divided doses (50 mg three times daily) 3, 2
- Children <50 kg: 75 mg elemental zinc daily in three divided doses (25 mg three times daily) 3, 2
- Minimum effective daily dose is 75 mg, which must be divided into at least two doses to be effective 4
Administration Timing
- Take 30 minutes before meals to maximize absorption 3, 5, 2
- In rare cases of gastric intolerance with morning dose, may take between breakfast and lunch 2
- Capsules must be swallowed whole, not opened or chewed 2
Important Limitations
- Not recommended for initial therapy of symptomatic patients due to delayed onset of action from zinc-induced metallothionein synthesis 2
- Symptomatic patients should be treated initially with chelating agents, then transitioned to zinc for maintenance once clinically stable 2
Monitoring Parameters
For Penicillamine
- 24-hour urinary copper excretion: should be 200-500 μg (3-8 μmol) per day on treatment 1
- Non-ceruloplasmin-bound copper: should normalize with effective treatment 1
- Regular monitoring for proteinuria, hematuria, CBC for bone marrow toxicity 1
For Zinc Acetate
- 24-hour urinary copper excretion: should be <125 μg (<2 μmol) per 24 hours on stable treatment 1, 2
- Non-ceruloplasmin plasma copper: keep below 20 μg/dL 2
- Urinary zinc levels may be measured to check compliance 1
- Monitor serum zinc levels and alkaline phosphatase periodically 5
Drug Interactions and Special Considerations
Critical Interaction
- If using both zinc and copper chelators, separate dosing by 5-6 hours to avoid neutralization of efficacy 3
- Zinc chelates iron; avoid coadministration with iron supplements 1
Pregnancy Considerations
- For penicillamine in Wilson's disease during pregnancy: limit to 750 mg/day; reduce to 250 mg/day for last 6 weeks if cesarean section planned 6
- Zinc acetate appears safer in pregnancy than penicillamine, though zinc does appear in breast milk and may cause copper deficiency in nursing infants 2, 6
Comparative Safety
- Recent meta-analysis shows zinc salts have lower incidence of adverse effects (RR: 2.42 for penicillamine vs zinc, p=0.014) and lower neurological deterioration (RR: 1.96 for penicillamine vs zinc, p=0.001) compared to penicillamine 7
- For neurological Wilson's disease specifically, zinc may be preferable as initial therapy given lower risk of neurological worsening 1, 7